{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:29:08Z","timestamp":1791919748345,"version":"4.3.4"},"reference-count":62,"publisher":"BMJ","issue":"12","license":[{"start":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T00:00:00Z","timestamp":1701820800000},"content-version":"unspecified","delay-in-days":5,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100022874","name":"Agendia","doi-asserted-by":"crossref","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100022874","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2023,10,20]]},"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Luminal B breast cancer (BC) presents a worse prognosis when compared with luminal A BC and exhibits a lower sensitivity to chemotherapy and a lower immunogenicity in contrast to non-luminal BC subtypes. The Neo-CheckRay clinical trial investigates the use of stereotactic body radiation therapy (SBRT) directed to the primary tumor in combination with the adenosine pathway inhibitor oleclumab to improve the response to neo-adjuvant immuno-chemotherapy in luminal B BC. The trial consists of a safety run-in followed by a randomized phase II trial. Here, we present the results of the first-in-human safety run-in.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The safety run-in was an open-label, single-arm trial in which six patients with early-stage luminal B BC received the following neo-adjuvant regimen: paclitaxel q1w\u00d712 \u2192 doxorubicin\/cyclophosphamide q2w\u00d74; durvalumab (anti-programmed cell death receptor ligand 1 (PD-L1)) q4w\u00d75; oleclumab (anti-CD73) q2w\u00d74 \u2192 q4w\u00d73 and 3\u00d78 Gy SBRT to the primary tumor at week 5. Surgery must be performed 2\u20136 weeks after primary systemic treatment and adjuvant therapy was given per local guidelines, RT boost to the tumor bed was not allowed. Key inclusion criteria were: luminal BC, Ki67\u226515% or histological grade 3, MammaPrint high risk, tumor size\u22651.5 cm. Primary tumor tissue samples were collected at three timepoints: baseline, 1 week after SBRT and at surgery. Tumor-infiltrating lymphocytes, PD-L1 and CD73 were evaluated at each timepoint, and residual cancer burden (RCB) was calculated at surgery.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Six patients were included between November 2019 and March 2020. Median age was 53 years, range 37\u201369. All patients received SBRT and underwent surgery 2\u20134 weeks after the last treatment. After a median follow-up time of 2 years after surgery, one grade 3 adverse event (AE) was reported: pericarditis with rapid resolution under corticosteroids. No grade 4\u20135 AE were documented. Overall cosmetical breast evaluation after surgery was \u2018excellent\u2019 in four patients and \u2018good\u2019 in two patients. RCB results were 2\/6 RCB 0; 2\/6 RCB 1; 1\/6 RCB 2 and 1\/6 RCB 3.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This novel treatment combination was considered safe and is worth further investigation in a randomized phase II trial.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>\n                     <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03875573\">NCT03875573<\/jats:ext-link>.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2023-007279","type":"journal-article","created":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T12:56:10Z","timestamp":1701867370000},"page":"e007279","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":27,"title":["First-in-human study of SBRT and adenosine pathway blockade to potentiate the benefit of immunochemotherapy in early-stage luminal B breast cancer: results of the safety run-in phase of the Neo-CheckRay trial"],"prefix":"10.1136","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct03875573","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03366844","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03804944","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04443348","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5989-7017","authenticated-orcid":false,"given":"Alex","family":"De Caluwe","sequence":"first","affiliation":[{"name":"Radiation Oncology, Universit\u00e9 libre de Bruxelles (ULB), H\u00f4pital Universitaire de Bruxelles (H.U.B), Institut Jules Bordet, Bruxelles, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Romano","sequence":"additional","affiliation":[{"name":"Medical Oncology, Center for Cancer Immunotherapy, Institut Curie, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Poortmans","sequence":"additional","affiliation":[{"name":"Radiation Oncology, Iridium Network and University of Antwerp, Antwerpen, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Gombos","sequence":"additional","affiliation":[{"name":"Medical Oncology, Universit\u00e9 libre de Bruxelles (ULB), H\u00f4pital Universitaire de Bruxelles (H.U.B), Institut Jules Bordet, Bruxelles, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Agostinetto","sequence":"additional","affiliation":[{"name":"Clinical Trials Support Unit (CTSU), Universit\u00e9 libre de Bruxelles (ULB), H\u00f4pital Universitaire de Bruxelles (H.U.B), Institut Jules Bordet, Bruxelles, Bruxelles, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilherme Nader","family":"Marta","sequence":"additional","affiliation":[{"name":"Clinical Trials Support Unit (CTSU), Universit\u00e9 libre de Bruxelles (ULB), H\u00f4pital Universitaire de Bruxelles (H.U.B), Institut Jules Bordet, Bruxelles, Bruxelles, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe","family":"Denis","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Libre de Bruxelles (ULB), H\u00f4pital Universitaire de Bruxelles (HUB), Institut Jules Bordet, Bruxelles, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stylianos","family":"Drisis","sequence":"additional","affiliation":[{"name":"Radiology, Universit\u00e9 libre de Bruxelles (ULB), H\u00f4pital Universitaire de Bruxelles (H.U.B), Institut Jules Bordet, Bruxelles, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Vandekerkhove","sequence":"additional","affiliation":[{"name":"Medical Physics, Universit\u00e9 libre de Bruxelles (ULB), H\u00f4pital Universitaire de Bruxelles (H.U.B), Institut Jules Bordet, Bruxelles, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Desmet","sequence":"additional","affiliation":[{"name":"Radiation Oncology, Universit\u00e9 libre de Bruxelles (ULB), H\u00f4pital Universitaire de Bruxelles (H.U.B), Institut Jules Bordet, Bruxelles, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Philippson","sequence":"additional","affiliation":[{"name":"Radiation Oncology, Universit\u00e9 libre de Bruxelles (ULB), H\u00f4pital Universitaire de Bruxelles (H.U.B), Institut Jules Bordet, Bruxelles, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ligia","family":"Craciun","sequence":"additional","affiliation":[{"name":"Pathology, Universit\u00e9 libre de Bruxelles (ULB), H\u00f4pital Universitaire de Bruxelles (H.U.B), Institut Jules Bordet, Bruxelles, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Veys","sequence":"additional","affiliation":[{"name":"Surgery, Universit\u00e9 libre de Bruxelles (ULB), H\u00f4pital Universitaire de Bruxelles (H.U.B), Institut Jules Bordet, Bruxelles, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Larsimont","sequence":"additional","affiliation":[{"name":"Pathology, Universit\u00e9 libre de Bruxelles (ULB), H\u00f4pital Universitaire de Bruxelles (H.U.B), Institut Jules Bordet, Bruxelles, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Paesmans","sequence":"additional","affiliation":[{"name":"Clinical Trials Support Unit (CTSU), Universit\u00e9 libre de Bruxelles (ULB), H\u00f4pital Universitaire de Bruxelles (H.U.B), Institut Jules Bordet, Bruxelles, Bruxelles, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Van Gestel","sequence":"additional","affiliation":[{"name":"Radiation Oncology, Universit\u00e9 libre de Bruxelles (ULB), H\u00f4pital Universitaire de Bruxelles (H.U.B), Institut Jules Bordet, Bruxelles, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Salgado","sequence":"additional","affiliation":[{"name":"Pathology, GasthuisZusters Antwerpen, Antwerpen, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Sotiriou","sequence":"additional","affiliation":[{"name":"Medical Oncology, Universit\u00e9 libre de Bruxelles (ULB), H\u00f4pital Universitaire de Bruxelles (H.U.B), Institut Jules Bordet, Bruxelles, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Piccart-Gebhart","sequence":"additional","affiliation":[{"name":"Medical Oncology, Universit\u00e9 libre de Bruxelles (ULB), H\u00f4pital Universitaire de Bruxelles (H.U.B), Institut Jules Bordet, Bruxelles, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michail","family":"Ignatiadis","sequence":"additional","affiliation":[{"name":"Medical Oncology, Universit\u00e9 libre de Bruxelles (ULB), H\u00f4pital Universitaire de Bruxelles (H.U.B), Institut Jules Bordet, Bruxelles, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3751-0819","authenticated-orcid":false,"given":"Laurence","family":"Buisseret","sequence":"additional","affiliation":[{"name":"Medical Oncology, Universit\u00e9 libre de Bruxelles (ULB), H\u00f4pital Universitaire de Bruxelles (H.U.B), Institut Jules Bordet, Bruxelles, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,12,6]]},"reference":[{"key":"2025100313042578000_11.12.e007279.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2112651"},{"key":"2025100313042578000_11.12.e007279.2","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.annonc.2022.07.1940","article-title":"Neoadjuvant Durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response","volume":"33","author":"Loibl","year":"2022","journal-title":"Annals of Oncology"},{"key":"2025100313042578000_11.12.e007279.3","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1001\/jamaoncol.2019.6650","article-title":"Effect of Pembrolizumab plus Neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer","volume":"6","author":"Nanda","year":"2020","journal-title":"JAMA Oncol"},{"key":"2025100313042578000_11.12.e007279.4","doi-asserted-by":"crossref","first-page":"S1260","DOI":"10.1016\/j.annonc.2023.10.011","article-title":"Lba21 KEYNOTE-756: phase III study of Neoadjuvant Pembrolizumab (Pembro) or placebo (PBO) + chemotherapy (Chemo), followed by adjuvant Pembro or PBO + endocrine therapy (ET) for early-stage high-risk ER+\/Her2\u2013 breast cancer","volume":"34","author":"Cardoso","year":"2023","journal-title":"Annals of Oncology"},{"key":"2025100313042578000_11.12.e007279.5","doi-asserted-by":"crossref","first-page":"S1259","DOI":"10.1016\/j.annonc.2023.10.010","article-title":"Lba20 A randomized, double-blind trial of Nivolumab (NIVO) vs placebo (PBO) with Neoadjuvant chemotherapy (NACT) followed by adjuvant endocrine therapy (ET) \u00b1 NIVO in patients (Pts) with high-risk, ER+ Her2\u2212 primary breast cancer (BC)","volume":"34","author":"Loi","year":"2023","journal-title":"Annals of Oncology"},{"key":"2025100313042578000_11.12.e007279.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62422-8"},{"key":"2025100313042578000_11.12.e007279.7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.1010"},{"key":"2025100313042578000_11.12.e007279.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1602253"},{"key":"2025100313042578000_11.12.e007279.9","doi-asserted-by":"crossref","first-page":"4141","DOI":"10.1245\/s10434-022-11666-2","article-title":"Age-independent preoperative Chemosensitivity and 5-year outcome determined by combined 70- and 80-gene signature in a prospective trial in early-stage breast cancer","volume":"29","author":"Whitworth","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"2025100313042578000_11.12.e007279.10","doi-asserted-by":"crossref","unstructured":"Gajewski TF , Corrales L , Williams J , et al . Cancer Immunotherapy Targets Based on Understanding the T Cell-Inflamed Versus Non-T Cell-Inflamed Tumor Microenvironment BT - Tumor Immune Microenvironment in Cancer Progression and Cancer Therapy. 2017: 31. doi:10.1007\/978-3-319-67577-0","DOI":"10.1007\/978-3-319-67577-0_2"},{"key":"2025100313042578000_11.12.e007279.11","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S1470-2045(17)30904-X","article-title":"Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with Neoadjuvant therapy","volume":"19","author":"Denkert","year":"2018","journal-title":"Lancet Oncol"},{"key":"2025100313042578000_11.12.e007279.12","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1158\/1078-0432.728.11.2","article-title":"Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer","volume":"11","author":"Demaria","year":"2005","journal-title":"Clin Cancer Res"},{"key":"2025100313042578000_11.12.e007279.13","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-0265"},{"key":"2025100313042578000_11.12.e007279.14","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15618","article-title":"DNA Exonuclease Trex1 regulates radiotherapy-induced tumour Immunogenicity","volume":"8","author":"Vanpouille-Box","year":"2017","journal-title":"Nat Commun"},{"key":"2025100313042578000_11.12.e007279.15","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0232-2"},{"key":"2025100313042578000_11.12.e007279.16","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1001\/jamaoncol.2019.1478","article-title":"Effect of Pembrolizumab after stereotactic body radiotherapy vs Pembrolizumab alone on tumor response in patients with advanced non\u2013small cell lung cancer","volume":"5","author":"Theelen","year":"2019","journal-title":"JAMA Oncol"},{"key":"2025100313042578000_11.12.e007279.17","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00149-2"},{"key":"2025100313042578000_11.12.e007279.18","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1001\/jamaoncol.2015.2756","article-title":"Role of local radiation therapy in cancer Immunotherapy","volume":"1","author":"Demaria","year":"2015","journal-title":"JAMA Oncol"},{"key":"2025100313042578000_11.12.e007279.19","doi-asserted-by":"crossref","unstructured":"Wennerberg E , Kawashima N , Demaria S . Adenosine regulates radiation therapy-induced anti-tumor immunity. J Immunotherapy Cancer 2015;3. doi:10.1186\/2051-1426-3-S2-P378","DOI":"10.1186\/2051-1426-3-S2-P378"},{"key":"2025100313042578000_11.12.e007279.20","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-19-0449"},{"key":"2025100313042578000_11.12.e007279.21","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2019-0904-SA"},{"key":"2025100313042578000_11.12.e007279.22","unstructured":"Edge S , Byrd DR , Compton CC , et al . Internet. AJCC Cancer Staging Manual 7th ed. Springer-Verlag New York, 2010: 648. Available: http:\/\/www.springer.com\/us\/book\/9780387884400"},{"key":"2025100313042578000_11.12.e007279.23","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198212000-00014"},{"key":"2025100313042578000_11.12.e007279.24","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-021-08601-1","article-title":"Neo-Checkray: radiation therapy and adenosine pathway blockade to increase benefit of Immuno-chemotherapy in early stage Luminal B breast cancer, a randomized phase II trial","volume":"21","author":"De Caluw\u00e9","year":"2021","journal-title":"BMC Cancer"},{"key":"2025100313042578000_11.12.e007279.25","unstructured":"National Cancer Institute [Internet] . Common terminology criteria for adverse events (CTCAE). 2018. Available: https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_5.0\/"},{"key":"2025100313042578000_11.12.e007279.26","unstructured":"MEDDRA . Medical dictionary for regulatory activities [Internet]. n.d. Available: https:\/\/www.meddra.org"},{"key":"2025100313042578000_11.12.e007279.27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.10.6823"},{"key":"2025100313042578000_11.12.e007279.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2022.05.005"},{"key":"2025100313042578000_11.12.e007279.29","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu450"},{"key":"2025100313042578000_11.12.e007279.30","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13235878","article-title":"Cd73-mediated immunosuppression is linked to a specific fibroblast population that paves the way for new therapy in breast cancer","volume":"13","author":"Magagna","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2025100313042578000_11.12.e007279.31","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-13-0180"},{"key":"2025100313042578000_11.12.e007279.32","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.171.4.1918"},{"key":"2025100313042578000_11.12.e007279.33","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.cmpb.2015.11.010","article-title":"The breast cancer conservative treatment. cosmetic results - BCCT.Core - software for objective assessment of esthetic outcome in breast cancer conservative treatment: A narrative review","volume":"126","author":"Cardoso","year":"2016","journal-title":"Comput Methods Programs Biomed"},{"key":"2025100313042578000_11.12.e007279.34","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.ijrobp.2012.10.034","article-title":"Phase 1 clinical trial of stereotactic body radiation therapy concomitant with Neoadjuvant chemotherapy for breast cancer","volume":"85","author":"Bondiau","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2025100313042578000_11.12.e007279.35","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1001\/jamaoncol.2016.1061","article-title":"Variation in the incidence and magnitude of tumor-infiltrating lymphocytes in breast cancer subtypes: A systematic review","volume":"2","author":"Stanton","year":"2016","journal-title":"JAMA Oncol"},{"key":"2025100313042578000_11.12.e007279.36","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1158\/2159-8290.CD-22-0475","article-title":"The great immune escape: understanding the divergent immune response in breast cancer subtypes","volume":"13","author":"Onkar","year":"2023","journal-title":"Cancer Discov"},{"key":"2025100313042578000_11.12.e007279.37","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1257452","article-title":"Tumor-infiltrating lymphocyte composition, organization and PD-1\/PD-L1 expression are linked in breast cancer","volume":"6","author":"Buisseret","year":"2017","journal-title":"Oncoimmunology"},{"key":"2025100313042578000_11.12.e007279.38","doi-asserted-by":"crossref","unstructured":"Debien V , De Caluw\u00e9 A , Wang X , et al . Immunotherapy in breast cancer: an overview of current strategies and perspectives. Npj Breast Cancer 2023;9. doi:10.1038\/s41523-023-00508-3","DOI":"10.1038\/s41523-023-00508-3"},{"key":"2025100313042578000_11.12.e007279.39","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-20138-8","article-title":"Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by Cd8+ T cells","volume":"11","author":"G\u00f3mez-Aleza","year":"2020","journal-title":"Nat Commun"},{"key":"2025100313042578000_11.12.e007279.40","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3492"},{"key":"2025100313042578000_11.12.e007279.41","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00589-1"},{"key":"2025100313042578000_11.12.e007279.42","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1245\/s10434-014-3908-y","article-title":"Chemosensitivity predicted by blueprint 80-gene functional subtype and Mammaprint in the prospective Neoadjuvant breast Registry Symphony trial (NBRST)","volume":"21","author":"Whitworth","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"2025100313042578000_11.12.e007279.43","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.504","article-title":"Pathologic complete response (pCR) rates for HR+\/Her2- breast cancer by molecular subtype in the I-Spy2 trial","volume":"40","author":"Huppert","year":"2022","journal-title":"JCO"},{"key":"2025100313042578000_11.12.e007279.44","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-1525"},{"key":"2025100313042578000_11.12.e007279.45","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2824"},{"key":"2025100313042578000_11.12.e007279.46","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0432-4"},{"key":"2025100313042578000_11.12.e007279.47","doi-asserted-by":"publisher","DOI":"10.1016\/S 1470-2045 (21)00658-6"},{"key":"2025100313042578000_11.12.e007279.48","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s00262-022-03253-x","article-title":"Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic Cervical or endometrial carcinoma: results of the phase II PRIMMO study","volume":"72","author":"De Jaeghere","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"2025100313042578000_11.12.e007279.49","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002485","article-title":"Neoadjuvant Immunoradiotherapy results in high rate of complete pathological response and clinical to pathological Downstaging in locally advanced head and neck squamous cell carcinoma","volume":"9","author":"Leidner","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2025100313042578000_11.12.e007279.50","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002038","article-title":"Radiation dose and fraction in immunotherapy: one-size regimen does not fit all settings, so how does one choose?","volume":"9","author":"Demaria","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2025100313042578000_11.12.e007279.51","doi-asserted-by":"crossref","unstructured":"Martinez AB , Bloy N , Hensler M , et al . 446 HR + breast cancer: defining innate and acquired resistance to immune Checkpoint inhibitors. SITC 37th Annual Meeting (SITC 2022) Abstracts; November 2022 doi:10.1136\/jitc-2022-SITC2022.0446","DOI":"10.1136\/jitc-2022-SITC2022.0446"},{"key":"2025100313042578000_11.12.e007279.52","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-3427"},{"key":"2025100313042578000_11.12.e007279.53","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.radonc.2021.10.005","article-title":"Unintended dose to the lower Axilla in adjuvant radiotherapy for breast cancer: differences between tangential beam and VMAT","volume":"164","author":"Ahrouch","year":"2021","journal-title":"Radiother Oncol"},{"key":"2025100313042578000_11.12.e007279.54","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djs629"},{"key":"2025100313042578000_11.12.e007279.55","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/s41571-020-0382-2","article-title":"The adenosine pathway in Immuno-oncology","volume":"17","author":"Allard","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"2025100313042578000_11.12.e007279.56","doi-asserted-by":"crossref","first-page":"698","DOI":"10.3389\/fimmu.2019.00698","article-title":"Targeting the immunomodulatory Cd73\/adenosine system to improve the therapeutic gain of radiotherapy","volume":"10","author":"de Leve","year":"2019","journal-title":"Front Immunol"},{"key":"2025100313042578000_11.12.e007279.57","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.22.00227","article-title":"COAST: an open-label, phase II, multidrug platform study of Durvalumab alone or in combination with Oleclumab or Monalizumab in patients with Unresectable, stage III non\u2013small-cell lung cancer","volume":"40","author":"Herbst","year":"2022","journal-title":"J Clin Oncol"},{"key":"2025100313042578000_11.12.e007279.58","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-006842","article-title":"Cd73 and PD-L1 dual blockade Amplifies antitumor efficacy of SBRT in murine PDAC models","volume":"11","author":"Ye","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2025100313042578000_11.12.e007279.59","doi-asserted-by":"publisher","DOI":"10.1096\/fj.201601228R"},{"key":"2025100313042578000_11.12.e007279.60","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-2310"},{"key":"2025100313042578000_11.12.e007279.61","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.semradonc.2022.01.001","article-title":"Immunotherapy combined with radiation therapy in breast cancer: A rapidly evolving landscape","volume":"32","author":"Santa-Maria","year":"2022","journal-title":"Semin Radiat Oncol"},{"key":"2025100313042578000_11.12.e007279.62","doi-asserted-by":"crossref","first-page":"D10","DOI":"10.1158\/1538-7445.SABCS21-PD10-01","article-title":"Abstract Pd10-01: the PEARL trial: pre-operative Pembrolizumab with radiation therapy in early stage triple negative breast cancer","volume":"82","author":"McArthur","year":"2022","journal-title":"Cancer Res"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2023-007279","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T20:04:37Z","timestamp":1759521877000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2023-007279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":62,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,12,6]]},"published-print":{"date-parts":[[2023,12]]}},"alternative-id":["10.1136\/jitc-2023-007279"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2023-007279","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12]]}}}